Nevertheless, despite the intra-tumor heterogeneity, HSP110 groups were comparable between ours and the two published studies with 21.3, 19, and 24% low expression of HSP110 and 78.7, 81, and 76% high expression of HSP110, respectively (Kim et al., 2014; Oh et al., 2017). The gene discussed is HSPH1; the disease is neoplasm.